Skip to main content

Advertisement

Figure 1 | BMC Cancer

Figure 1

From: Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

Figure 1

Examples of partial and mixed responses after DAB/IL2 administration. A. Anterior/posterior and lateral views of PET imaging reveal a large duodenal mass (arrow) and several hepatic metastases (box) at baseline and 1 month after the final cycle of DAB/IL2. PET imaging confirmed regression of the hepatic metastases (right panels) and a modest reduction in the duodenal mass. The increased 18 F-fluorodeoxyglucose uptake in the left kidney is due to hydronephrosis which is unrelated to melanoma. B. After 3 cycles of DAB/IL2, this patient experienced the marked regression of a large subcutaneous and a pelvic mass (see bottom 2 horizontal red arrows just above the bladder [which normally contains tracer]) and a peritoneal mass (right vertical arrow). Simultaneously, enlarged paratracheal lymph nodes worsened (upper arrows), a large conglomeration of left axillary masses expanded (dashed circle). An inferior peritoneal mass appeared and expanded (left vertical arrow) and a superior peritoneal mass expanded and then regressed with treatment (upper horizontal arrow).

Back to article page